A recent report published by Infinium Global Research on pharmaceutical continuous manufacturing market provides an in-depth analysis of segments and sub-segments in global as well as a regional pharmaceutical continuous manufacturing market. The study also highlights the impact of drivers, restraints and macro indicators on the global and regional pharmaceutical continuous manufacturing market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of the global pharmaceutical continuous manufacturing market. According to the report the global pharmaceutical continuous manufacturing market is projected to grow at a CAGR of 8.2% over the forecast period of 2018-2024. In 2016, it was worth USD 1.9 billion and it is anticipated to reach USD 3.0 billion by 2024.
A method used to manufacture or process raw material without interruption is called continuous manufacturing or flow production. Continuous manufacturing is contrasted with batch production. Pharmaceutical continuous manufacturing technology reduces manual intervention due to controlled units that provide a high level of automation. These units operate 24 hours per day, seven days per week with rare maintenance shutdowns, thus increasing and utilizing the production capacity and profitability. This technology helps in reducing inconsistency; higher yields; increased profitability; and lower manufacturing and equipment cost.
Productive capacity is the maximum possible output of an economy. According to the United Nations Conference on Trade and Development (UNCTAD), no agreed-upon definition of maximum output exists. Hence utilization of production capacity in continuous manufacturing is driving the growth of the market significantly. This manufacturing technology provides a better way of manufacturing drug products that save time, improve quality, create more flexibility in production quantities, reduce required production and the material that is to be developed this may turn into the additional positive factor driving the demand growth. Moreover, FDA has developed a program on the advancement of emerging technology applications to modernize pharmaceutical manufacturing base and frequent discussion with the agency before the implementation of manufacturing technology. However, the high implementation cost of automated units for continuous manufacturing is likely to restrain the growth of the market. The Merger and acquisition and joint venture among the leading player will bring more opportunities to this market.
Europe is expected to be the largest market for pharmaceutical continuous manufacturing followed by Asia-Pacific. The demand for advanced technology from is high and the presence of many contract manufacturing organization has boosted the market in the region. The U.K. and Germany are the leading revenue generating countries in this region. The growth in the Asia Pacific is mainly driven by China and India, due to the presence of the number of contract manufacturing companies. Growing suitability of technologically advanced continuous manufacturing and rising awareness about the advantages of technology, China is considered to be the largest market in this region.
With the new level of productivity, Siemens is working to develop experimental plants with the help of continuous manufacturing, they are working in collaboration with the number of pharmaceutical companies as well as the original equipment manufacturers. Initiatives by FDA to switch from current batch process to continuous manufacturing technology drives interest among the pharmaceutical companies, for instance in 2016, the FDA approved Johnson & Johnson’s switch from batch to continuous manufacturing for the production of Prezista, a drug used to treat HIV. Moreover, in 2017 Seimens has signed a partnership with GEA to bring integrated continuous manufacturing of tablets. On the other hand, GlaxoSmithKline has collaborated with Pfizer, GEA and G-CON Manufacturing to design a next-generation portable, continuous, miniature and modular (PCMM) prototype for development, clinical trials, and commercial manufacturing.
The report on the global pharmaceutical continuous manufacturing market covers segments such as distribution channel, application type, and end user. On the basis of distribution channel, the global pharmaceutical continuous manufacturing market is categorized into hospital pharmacy, retail pharmacy, and online pharmacy. On the basis of application type, the global pharmaceutical continuous manufacturing market is categorized into active pharmaceutical ingredient, dry powders, and biologics. On the basis of end user, the global pharmaceutical continuous manufacturing market is categorized into pharmaceutical companies and contract manufacturing organization.
The report provides regional analysis covering geographies such as North America, Europe, Asia-Pacific, and Rest of the World. In this section, the key trends and market size for each geography are provided over the period of 2016-2024.
The countries covered in the North America region include the U.S., Canada, and Mexico; while Asia-Pacific includes China, Japan, India, South Korea, Malaysia, and among others. Moreover, Germany, U.K., France, Spain, and Rest of Europe are included in the European region. The U.S. drives the growth in the North America region as it is the largest market in the region. The Asia-pacific region offers a substantial potential for the market growth owing to rapid growth in markets such as India and China. The APAC region is projected to experience growth at a CAGR of x.x% over the period of 2018-2024.
The report provides profiles of the companies in the global pharmaceutical continuous manufacturing market such as Johnson & Johnson’s, GEA, Korsch AG, Siemens AG, Corning Life Sciences, Continuous Pharmaceutical, Scott Equipment Company, S K Biotek Ltd, Chemtrix and Others.
The report provides deep insights on demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the global pharmaceutical continuous manufacturing market. Moreover, IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of pharmaceutical continuous manufacturing market. Moreover, the study highlights current market trends and provides forecast from 2018-2024. We also have highlighted future trends in the pharmaceutical continuous manufacturing market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players. This report will help manufacturers, suppliers, and distributors of the pharmaceutical continuous manufacturing market to understand the present and future trends in this market and formulate their strategies accordingly.